4
Changes in Ownership
Allogene Therapeutics, Inc. Filed Acc 0001209191-18-055372
Director bought 35,000 shares at $18.00 ($630,000)
- Director acquired 7,628,936 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Belldegrun Arie Director | 2018-10-15 | Purchase | +35,000 | $18.00 | $630,000 | 35,000 | D: show line 1 in the form |
| Belldegrun Arie Director | 2018-10-15 | Conversion | +142,248 | 3,710,006 | I: show line 2 in the form | ||
| Belldegrun Arie Director | 2018-10-15 | Conversion | +5,989,352 | 5,989,352 | I: show line 3 in the form | ||
| Belldegrun Arie Director | 2018-10-15 | Conversion | +1,497,336 | 1,497,336 | I: show line 4 in the form | ||
| Open-market purchases · 35,000 sh · avg $18.00 · $630,000 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Belldegrun Arie Director | 2018-10-15 | Conversion · Series A Convertible Preferred Stock | −27,095 | 0 | I: show line 5 in the form | |||||
| Belldegrun Arie Director | 2018-10-15 | Conversion · Series A Convertible Preferred Stock | −1,140,829 | 0 | I: show line 6 in the form | |||||
| Belldegrun Arie Director | 2018-10-15 | Conversion · Series A Convertible Preferred Stock | −285,207 | 0 | I: show line 7 in the form |
Loading xslF345X03/doc4.xml…